NOVEL SUBCUTANEOUS SUSTAINED RELEASE NANOPARTICLES ENCAPSULATING LOW MOLECULAR WEIGHT HEPARIN (LMWH): PREPARATION, CHARACTERIZATION AND EVALUATION
Keywords:
Low molecular weight heparin, Subcutaneous, Stability, Polycaprolactone, Venous thrombosis, activated partial thromboplastin timeAbstract
Objective: The objective of the current research work was to prepare and evaluate novel subcutaneous sustained release polymeric nanoparticles for low molecular weight heparin (LMWH).
Methods: In this study, we prepared subcutaneously administered polymeric nanoparticles encapsulating LMWH using different grades of polycaprolactons (PCL) (14k, 45k, 80k) and 0.1% Polyvinyl alcohol (PVA) solution as surfactant by employing water–in-oil in-water (w/o/w) emulsion and evaporation method. The formulated nanoparticles were evaluated for size, shape, zeta potential, in vitro drug release, and in vivo biological activity (anti factor Xa activity) using standard kit, antithrombotic activity in thrombosis induced rat model. Drug and polymer interactions in the nanoparticles were evaluated using Fourier Transform Infrared Spectroscopy (FTIR), X-ray Diffraction (XRD).
Results: Scanning electron microscopic (SEM) studies on the nanoparticles confirmed the formation of spherical particles with smooth surface. The size of the formed nanoparticles were about 415-495 nm. The % entrapment of nanoparticles was found to be between 69-81%. Nanoparticles showed slow and sustained pattern of release for about 59-65 % in 48 h. Optimized nanoparticles exhibited excellent improvement in pharmacokinetic parameters and showed good antithrombotic activity, Activated partial thromboplastin time (aPTT) activity when compared to free drug. FTIR studies indicated that there was no loss in chemical integrity of the drug upon fabrication into nanoparticles. XRD results demonstrated that the drug changed its physical form in the formulation.
Conclusion: The results of this study revealed that subcutaneous nanoparticles were excellent candidates for sustained drug delivery of LMWH to avoid repeated subcutaneous administration.
Keywords: Low molecular weight heparin, Subcutaneous, Stability, Polycaprolactone, Venous thrombosis, Activated partial thromboplastin time
Â
Downloads
References
White RH. The epidemiology of venous thromboembolism. Circulation 2003;107:4-8.
Goldhaber SZ. Risk factors for venous thromboembolism. J Am Coll Cardiol 2010;56:1-7.
Hirsh J, Warkentin TE, Shaughnessy SG, Anand SS, Halperin JL, Raschke R, et al. Heparin and low molecular weight heparin mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001;119:64-94.
Jogala S, Rachamalla SS, Aukunuru JV. Development of subcutaneous sustained release nanoparticles encapsulating LMWH. J Adv Pharm Technol Res 2015;6:58-64.
Pazzini C, Priscyla DM, Lucas BP, Aline MA, Nelci FH, Silmara M, et al. Polymeric nanoparticles of enoxaparin as a delivery system: in vivo evaluation in normal rats and in a venous thrombosis rat model. J Nanosci Nanotechnol 2015;15:4837-43.
Yerragunta B, Jogala S, Chinnala KM, Aukunuru J. Development of a novel 3-month drug releasing risperidone microspheres. J Pharm BioAllied Sci 2015;7:37-44.
Navitha A, Satheesh S, Krishnamohan C, Jithan A. Development of novel risperidone implants using blends of polycaprolactones and in vitro in vivo correlation studies. J Adv Pharm Technol Res 2014;5:84-9.
Kompella UB, Bandi N, Ayalasomayajula SP. Subconjunctival nano-and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Visual Sci 2003;44:1192-201.
Aukunuru JV, Ayalasomayajula SP, Kompella UB. Nanoparticle formulation enhances the delivery and activity of a vascular endothelial growth factor antisense oligonucleotide in human retinal pigment epithelial cells. J Pharm Pharmacol 2003;55:1199-206.
Choubey AK, Dora CP, Bhatt TD, Gill MS, Suresh S. Development and evaluation of PEGylated Enoxaparin: a novel approach for enhanced anti-Xa activity. Bioorg Chem 2014;54:1-6.
Jogala S, Rachamalla SS, Aukunuru J. Development of PEG-PLGA based intravenous low molecular weight heparin (LMWH) nanoparticles intended to treat venous thrombosis. Curr Drug Delivery 2016;13:00-00.
Hoffart V, Lamprecht A, Maincent P, Lecompte T, Vigneron C, Ubrich N. Oral bioavailability of a low molecular weight heparin using a polymeric delivery system. J Controlled Release 2006;113:38-42.
Sridhar A, Jithan AV, Malla Reddy V. Comparative pharmacokinetics of free and liposomeÂencapsulated catechin after intravenous and intraperitoneal administration. Int J Pharm Sci Nanotechnol 2008;1:152Â9.
Konatham S, Nyathani HK, Bonepally CR, Yannamaneni PK, Aukunuru J. Liposomal delivery of curcumin to liver. Turk J Pharm Sci 2010;7:89Â98.
Marcato PD, Caverzan J, Bergmann BR, Pinto EF, Machado D, Silva RA, et al. Nanostructured polymer and lipid carrers for sunscreen. Biological effects and skin permeation. J Nanosci Nanotechnol 2011;11:1880-6.
Wang C, Yang F, Xu Z, Shi D, Chen D, Dai J, et al. Intravenous release of NO from lipidic microbubbles accelerates deep vein thrombosis resolution in a rat model. Thromb Res 2013;131:31-8.
Shahbazia MA, Hamidib M, Soliman MS. Preparation, optimization, and in vitro/in vivo/ex-vivo characterization of chitosan-heparin nanoparticles: drug-induced gelation. J Pharm Pharmacol 2013;65:1118–33.
Wang S, Guo S, Cheng L. Disodium norcantharidate loaded poly–caprolactone microspheres: preparation and evaluation. Int J Pharm 2008;350:130–7.
Chawla JS, Amiji MM. Biodegradable poly(epsilon–caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen. Int J Pharm 2002;249;127–38.